Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4947298 | 0.98 | TSHR (0.58) | TSHRALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL4941219 | 0.95 | TSHR (0.58) | TSHRALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL4944943 | 0.93 | TSHR (0.58) | TSHRALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL4947171 | 0.92 | TSHR (0.48) | TSHRALDH1A1NPSR1HPGDUSP2 | |
| SCHEMBL4946812 | 0.90 | TSHR (0.54) | TSHRALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL4941312 | 0.89 | ALDH1A1 (0.62) | TSHRALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL4945681 | 0.89 | KDM4E (0.47) | TSHRALDH1A1NPSR1HPGDUSP2 | |
| SCHEMBL4945036 | 0.88 | ALDH1A1 (0.56) | TSHRALDH1A1NPSR1HPGDUSP2 | |
| SCHEMBL4943892 | 0.88 | ALDH1A1 (0.54) | TSHRALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL4943863 | 0.87 | TSHR (0.53) | TSHRALDH1A1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | claimed |
| EP-1458381-B1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-30 | — | — | EP | claimed |
| US-20050187275-A1 | Triazoles as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-08-25 | — | — | US | claimed |
| EP-1458381-A1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | Applied Research Systems ARS Holding N.V. (AN) | 2004-09-22 | — | — | EP | claimed |
| WO-2003053437-A1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-07-03 | — | — | WO | claimed |
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | disclosed |
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | disclosed |
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | disclosed |
| US-20050187275-A1 | Triazoles as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187275-A1 | Triazoles as oxytocin antagonists | OXTR, AVPR2, AVPR1B | TSHR 148/4885ALDH1A1 4091/4885MEN1 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.